LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Publisher: Wydawnictwo Via Medica
Languages: English
Types: Article
Subjects:
Background: Heart rate (HR) is an important risk factor in coronary artery disease (CAD). However, there is little contemporary data on HR and the use of HR-lowering medications, particularly beta-blockers, among patients with stable CAD in routine clinical practice.

\ud \ud Aim: To describe HR in the Polish population of the CLARIFY registry, overall and in relation to beta-blocker use, and to assess the determinants of HR.

\ud \ud Methods and results: CLARIFY is an international, prospective, observational, longitudinal registry of outpatients with stable CAD, defined as either prior myocardial infarction or revascularisation procedure, or evidence of coronary stenosis of at least 50%, or chest pain associated with proven myocardial ischaemia. A total of 33,438 patients from 45 countries in Europe, the Americas, Africa, the Middle East, and Asia/Pacific were enrolled between November 2009 and July 2010. In Poland, 1,004 patients were enrolled between February and June 2010, which was the largest population among countries from Eastern Europe. Most patients were men (72.8%). Mean ± SD age was 62.1 ± 9.1 years. HR determined by pulse was 69.3 ± 9.4 bpm and by electrocardiogram was 68.2 ± 10.6 bpm. Beta-blockers were used in 89.9% of patients. Resting HR ≥ 70 bpm was noted in 49.3% of all patients and in 48.6% of patients on beta-blockers. Resting HR ≥ 70 bpm was significantly more frequent among younger patients, and in those with diabetes, those being treated for arterial hypertension, and who lacked regular physical activity. Patients with HR ≥ 70 bpm at rest had more frequent symptoms of angina and more frequently needed hospitalisation due to heart failure.

\ud \ud Conclusions: Despite a very high rate of beta-blocker use, almost 50% of patients with stable CAD had a resting HR ≥ 70 bpm, which was associated with more frequent angina and ischaemia. Further HR lowering is possible in many patients with CAD. Whether or not this will improve symptoms and outcomes is under investigation.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet, 1997; 349: 1269-1276.
    • 2. Anderson GF, Chu E. Expanding priorities-confronting chronic disease in countries with low income. N Engl J Med, 2007; 356: 209-211.
    • 3. Steg PG. Heart rate management in coronary artery disease: the CLARIFY registry. Eur Heart J, 2009 11 (suppl. D): D13-D18.
    • 4. Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting 2005; 26: 967-974.
    • 5. Kolloch R, Legler UF, Champion A et al. Impact of resting heart rate on outcomes in VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J, 2008; 29: 1327-1334.
    • 6. Fox K, Borer JS, Camm AJ et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol, 2007; 50: 823-830.
    • 7. Fox K, Ford I, Steg PG et al. Heart rate as a prognostic risk factor in patients with randomized, controlled BEAUTIFUL trial. Eur Heart J, 2009; 30: 2337-2345.
    • 13. Antoni ML, Boden H, Delgado V et al. Relationship between discharge heart rate and percutaneous coronary intervention. Eur Heart J, 2012; 33: 96-102.
    • 14. Rambihar S, Gao P, Teo K et al. Heart rate is associated with increased risk of major Cardiol, 1999; 33: 2092-2197.
    • 18. Banasiak W, Wilkins A, Ponikowski P et al. Pharmacotherapy in patients with stable 10.1371/journal.pone.0036284. Epub 2012 May 3.
    • 21. Fox K, Garcia MA, Ardissino Det al. Guidelines on the management of stable angina Cardiol, 2007; 50: 2264-2274.
    • 23. Bagnall AJ, Yan AT, Yan RT et al. Optimal medical therapy for non-ST-segment1927-1936 25. Fox K et al. Rationale, design, and baseline characteristics of the Study assessInG the
  • Inferred research data

    The results below are discovered through our pilot algorithms. Let us know how we are doing!

    Title Trust
    73
    73%
  • No similar publications.

Share - Bookmark

Cite this article